{"filing":{"accession_number":"0001104659-26-066317","cik":"0001650664","ticker":"EDIT","company_name":"Editas Medicine, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"tm2615565d3_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650664/000110465926066317/tm2615565d3_8k.htm"},"events":[{"id":8980,"run_id":7883,"accession_number":"0001104659-26-066317","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"Editas Medicine entered into an underwriting agreement on May 26, 2026 to conduct a public offering of 55,555,556 shares of common stock at $2.25 per share, together with accompanying warrants, generating approximately $117.0 million in net proceeds. The offering, which will fund operations into H2 2028, represents a material registered public offering that will dilute existing shareholders, with the warrant component potentially generating an additional $192.5 million upon exercise.","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1446,"accession_number":"0001104659-26-066317","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Editas Medicine entered into an underwriting agreement on May 26, 2026 to conduct a public offering of 55,555,556 shares of common stock at $2.25 per share, together with accompanying warrants, generating approximately $117.0 million in net proceeds. This is a material registered public offering of equity securities that will dilute existing shareholders. While technically a registered offering (not a private placement), the scale and nature of the issuance—combined with the warrant component that could generate an additional $192.5 million upon exercise—represents a significant dilutive capital raise material to investors' assessment of the company's equity structure and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:08:35.272833+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1447,"accession_number":"0001104659-26-066317","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses pricing of an \"underwritten public offering\" with net proceeds that will fund operations into H2 2028, indicating a material equity or debt issuance. While the specific terms are referenced in Exhibit 99.1 (the press release), the Item 8.01 disclosure itself confirms a capital raise event. For a biotech company like Editas Medicine with limited cash runway, a public offering is a material dilutive event affecting shareholder interests, though the classification as dilutive_issuance is somewhat inferred from context rather than explicit language in this excerpt.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:08:35.272833+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1446,"accession_number":"0001104659-26-066317","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Editas Medicine entered into an underwriting agreement on May 26, 2026 to conduct a public offering of 55,555,556 shares of common stock at $2.25 per share, together with accompanying warrants, generating approximately $117.0 million in net proceeds. This is a material registered public offering of equity securities that will dilute existing shareholders. While technically a registered offering (not a private placement), the scale and nature of the issuance—combined with the warrant component that could generate an additional $192.5 million upon exercise—represents a significant dilutive capital raise material to investors' assessment of the company's equity structure and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:08:35.272833+00:00","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-05-26"},{"id":1447,"accession_number":"0001104659-26-066317","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses pricing of an \"underwritten public offering\" with net proceeds that will fund operations into H2 2028, indicating a material equity or debt issuance. While the specific terms are referenced in Exhibit 99.1 (the press release), the Item 8.01 disclosure itself confirms a capital raise event. For a biotech company like Editas Medicine with limited cash runway, a public offering is a material dilutive event affecting shareholder interests, though the classification as dilutive_issuance is somewhat inferred from context rather than explicit language in this excerpt.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:08:35.272833+00:00","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-05-26"}]}